Pier 88 Investment Partners LLC Has $356,000 Stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Pier 88 Investment Partners LLC lowered its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 13.0% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 3,090 shares of the company’s stock after selling 460 shares during the period. Pier 88 Investment Partners LLC’s holdings in Neurocrine Biosciences were worth $356,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. 1832 Asset Management L.P. lifted its holdings in Neurocrine Biosciences by 1,370.7% in the 2nd quarter. 1832 Asset Management L.P. now owns 541,200 shares of the company’s stock worth $74,507,000 after purchasing an additional 504,400 shares during the last quarter. Los Angeles Capital Management LLC lifted its position in shares of Neurocrine Biosciences by 639.6% during the 3rd quarter. Los Angeles Capital Management LLC now owns 420,748 shares of the company’s stock worth $48,479,000 after purchasing an additional 363,863 shares during the last quarter. AQR Capital Management LLC grew its holdings in Neurocrine Biosciences by 23.0% in the 2nd quarter. AQR Capital Management LLC now owns 1,223,055 shares of the company’s stock valued at $166,959,000 after buying an additional 228,444 shares during the last quarter. Vanguard Group Inc. increased its position in Neurocrine Biosciences by 2.3% in the 1st quarter. Vanguard Group Inc. now owns 9,930,926 shares of the company’s stock worth $1,369,673,000 after buying an additional 220,598 shares during the period. Finally, Iron Triangle Partners LP acquired a new position in shares of Neurocrine Biosciences during the first quarter worth approximately $30,342,000. Institutional investors own 92.59% of the company’s stock.

Neurocrine Biosciences Trading Down 1.2 %

NBIX stock opened at $125.51 on Thursday. The stock has a market cap of $12.71 billion, a PE ratio of 33.65 and a beta of 0.35. The stock has a 50-day moving average price of $118.47 and a two-hundred day moving average price of $132.93. Neurocrine Biosciences, Inc. has a 1 year low of $107.84 and a 1 year high of $157.98.

Analysts Set New Price Targets

Several research firms recently commented on NBIX. BMO Capital Markets reduced their price target on shares of Neurocrine Biosciences from $128.00 to $114.00 and set a “market perform” rating for the company in a report on Thursday, October 17th. Needham & Company LLC restated a “hold” rating on shares of Neurocrine Biosciences in a research report on Monday. HC Wainwright reaffirmed a “buy” rating and issued a $190.00 price target on shares of Neurocrine Biosciences in a research note on Friday, November 1st. Oppenheimer increased their price objective on Neurocrine Biosciences from $216.00 to $219.00 and gave the stock an “outperform” rating in a research note on Friday, August 2nd. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $155.00 target price on shares of Neurocrine Biosciences in a report on Monday, September 16th. Five equities research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Neurocrine Biosciences has a consensus rating of “Moderate Buy” and a consensus target price of $163.91.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.